Leerink Partners Research analyst looking at data on a computer screen

Research Archive

Original Insights and Analysis

ASCO: More Room for SMMT / BNTX Upside; Unlikely w/ Higher H-6 OS Expectations

CRUSH RFI Debate Ongoing, but Risks Appear Overblown & Timing Unclear

Foundations of Discovery, Drugs & Dx: Key Takeawaysfrom Dx & NGS Panel

Paying to Cut the Line at FDA Is Still a Thing; A Look at PRVs and Their Value

LOE Cliffs to Overcome for Large-Cap Biopharma